金陵藥業(000919.SZ):擬與艾德凱騰簽署合作協議 共同研發“間苯三酚原料藥和口崩片”項目
格隆匯8月31日丨金陵藥業(000919.SZ)公佈,公司擬與南京艾德凱騰生物醫藥有限責任公司(簡稱“艾德凱騰”)簽署《合作協議》,共同合作研發“間苯三酚原料藥和口崩片”項目(以下簡稱“本項目”或“項目”)。鑑於藥物研發週期較長,本項目能否最終研發成功存在不確定性,公司將根據《深圳證券交易所股票上市規則》(以下簡稱“《股票上市規則》”)、《公司章程》等相關規定履行後續信息披露義務,敬請廣大投資者注意投資風險。
2023年8月30日,公司第九屆董事會第三次會議以9票同意,0票反對,0票棄權,審議通過了《關於擬與關聯方簽署合作協議暨關聯交易的議案》,本議案無關聯董事迴避表決。本項目研發經費預算為6000萬元,由公司與艾德凱騰共同合作研發,公司向艾德凱騰支付研發經費1920萬元以獲得本項目32%的項目權益,艾德凱騰享有68%的項目權益;公司最終以項目審計結果確認支付研發經費的金額以及項目權益比例。同日,公司與艾德凱騰簽署了《合作協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.